SG10201907161YA - Antibodies directed against lymphocyte activation gene 3 (lag-3) - Google Patents
Antibodies directed against lymphocyte activation gene 3 (lag-3)Info
- Publication number
- SG10201907161YA SG10201907161YA SG10201907161YA SG10201907161YA SG10201907161YA SG 10201907161Y A SG10201907161Y A SG 10201907161YA SG 10201907161Y A SG10201907161Y A SG 10201907161YA SG 10201907161Y A SG10201907161Y A SG 10201907161YA SG 10201907161Y A SG10201907161Y A SG 10201907161YA
- Authority
- SG
- Singapore
- Prior art keywords
- lag
- lymphocyte activation
- activation gene
- chain polypeptide
- directed against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562111486P | 2015-02-03 | 2015-02-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201907161YA true SG10201907161YA (en) | 2019-09-27 |
Family
ID=56564868
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201907161YA SG10201907161YA (en) | 2015-02-03 | 2016-02-03 | Antibodies directed against lymphocyte activation gene 3 (lag-3) |
SG11201706199RA SG11201706199RA (en) | 2015-02-03 | 2016-02-03 | Antibodies directed against lymphocyte activation gene 3 (lag-3) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201706199RA SG11201706199RA (en) | 2015-02-03 | 2016-02-03 | Antibodies directed against lymphocyte activation gene 3 (lag-3) |
Country Status (15)
Country | Link |
---|---|
US (3) | US10836824B2 (fr) |
EP (2) | EP3253798A4 (fr) |
JP (1) | JP6949713B2 (fr) |
KR (1) | KR20170116067A (fr) |
CN (2) | CN114634573A (fr) |
BR (1) | BR112017016638B1 (fr) |
CA (1) | CA2975753A1 (fr) |
EA (1) | EA201791742A1 (fr) |
HK (2) | HK1246814A1 (fr) |
IL (1) | IL253718B (fr) |
MA (1) | MA41463A (fr) |
MX (2) | MX2017009904A (fr) |
SG (2) | SG10201907161YA (fr) |
WO (1) | WO2016126858A2 (fr) |
ZA (1) | ZA201705303B (fr) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
EP3356411B1 (fr) | 2015-10-02 | 2021-06-30 | F. Hoffmann-La Roche AG | Anticorps bispécifiques pour pd1 et tim3 |
MX2018007406A (es) | 2015-12-16 | 2018-08-15 | Merck Sharp & Dohme | Anticuerpos anti-lag3 y fragmentos de enlace al antigeno. |
CN109475603B (zh) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | 抗pd-l1抗体 |
CA3037380A1 (fr) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anticorps anti-lag-3 et leurs procedes d'utilisation |
KR20230136711A (ko) | 2016-10-13 | 2023-09-26 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 항-lag-3 항체 및 조성물 |
AU2017354070A1 (en) | 2016-11-01 | 2019-05-16 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (PD-1) |
EP3689419A1 (fr) | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
TWI793094B (zh) | 2017-01-09 | 2023-02-21 | 美商提薩羅有限公司 | 用抗tim-3抗體治療癌症之方法 |
BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
EA201991673A1 (ru) | 2017-02-10 | 2020-01-17 | Регенерон Фармасьютикалз, Инк. | Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации |
CA3053989A1 (fr) * | 2017-02-22 | 2018-08-30 | I-Mab | Anticorps anti-lag-3 et leurs utilisations |
PT3606946T (pt) | 2017-04-03 | 2022-10-17 | Hoffmann La Roche | Imunoconjugados de um anticorpo anti-pd-1 com uma il-2 mutante ou com il-15 |
JP2020513009A (ja) * | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブSymphogen A/S | Pd−1、tim−3、およびlag−3を標的とする併用治療 |
MA49034B1 (fr) | 2017-04-05 | 2022-09-30 | Hoffmann La Roche | Anticorps anti-lag3 |
CN110506059B (zh) | 2017-04-05 | 2023-01-17 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
BR112019022515A2 (pt) * | 2017-04-27 | 2020-06-16 | Tesaro, Inc. | Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos |
JP2020520921A (ja) | 2017-05-18 | 2020-07-16 | テサロ, インコーポレイテッド | 癌を処置する併用療法 |
BR112019020610A2 (pt) | 2017-05-30 | 2020-04-22 | Bristol-Myers Squibb Company | tratamento de tumores positivos para o lag-3 |
CA3060989A1 (fr) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprenant une combinaison d'un anticorps anti-lag-3, d'un inhibiteur de voie pd-1 et d'un agent immunotherapeutique |
CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
KR20200042937A (ko) | 2017-08-30 | 2020-04-24 | 페인스 테라퓨틱스 인코포레이티드 | 항-lag-3 항체 및 이의 용도 |
CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
AU2018338901A1 (en) | 2017-09-30 | 2020-05-07 | Tesaro, Inc. | Combination therapies for treating cancer |
MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
JP2021511793A (ja) | 2018-01-31 | 2021-05-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Lag3に結合する抗原結合部位を含む二重特異性抗体 |
CN110305215B (zh) * | 2018-03-20 | 2023-11-03 | 基石药业 | 新型抗lag-3抗体多肽 |
JP7438180B2 (ja) | 2018-03-20 | 2024-02-26 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗lag-3抗体ポリペプチド |
CN110343178B (zh) * | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | 抗人lag-3单克隆抗体及其应用 |
CN110615840A (zh) * | 2018-06-19 | 2019-12-27 | 信达生物制药(苏州)有限公司 | 全人源的抗lag-3抗体及其应用 |
US11945864B2 (en) | 2018-06-29 | 2024-04-02 | Y-Biologics Inc. | Monoclonal antibody specifically binding to LAG-3 and use thereof |
SG11202100693UA (en) | 2018-07-26 | 2021-02-25 | Bristol Myers Squibb Co | Lag-3 combination therapy for the treatment of cancer |
TW202024638A (zh) | 2018-09-04 | 2020-07-01 | 美商泰沙羅公司 | 治療癌症之方法 |
EP3860988A1 (fr) | 2018-10-03 | 2021-08-11 | Tesaro, Inc. | Formes cristallines d'une base libre de niraparib |
CN113166071A (zh) | 2018-10-03 | 2021-07-23 | 特沙诺有限公司 | 尼拉帕利盐 |
EA202191086A1 (ru) | 2018-10-19 | 2021-09-20 | Бристоль-Мейерз Сквибб Компани | Комбинированная терапия меланомы |
US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
JP2022534967A (ja) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | 多腫瘍遺伝子シグネチャーおよびその使用 |
CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
CN112010972B (zh) * | 2019-05-31 | 2023-01-10 | 瑞阳(苏州)生物科技有限公司 | 与人lag-3蛋白结合的抗体及其编码基因和应用 |
WO2021024020A1 (fr) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Polythérapie impliquant des anticorps dirigés contre la claudine 18.2 et inhibiteurs de point de contrôle immunitaire pour le traitement du cancer |
KR20220066334A (ko) | 2019-09-22 | 2022-05-24 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 길항제 요법에 대한 정량적 공간 프로파일링 |
WO2021092220A1 (fr) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle |
WO2021092221A1 (fr) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle |
KR20220093349A (ko) | 2019-11-08 | 2022-07-05 | 브리스톨-마이어스 스큅 컴퍼니 | 흑색종에 대한 lag-3 길항제 요법 |
CN115298218A (zh) | 2019-12-18 | 2022-11-04 | 特沙诺有限公司 | 生物药物组合物和相关方法 |
EP4100426A1 (fr) | 2020-02-06 | 2022-12-14 | Bristol-Myers Squibb Company | Il-10 et ses utilisations |
MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
BR112023003427A2 (pt) | 2020-08-28 | 2023-03-21 | Bristol Myers Squibb Co | Terapia com antagonista de lag-3 para carcinoma hepatocelular |
BR112023003553A2 (pt) | 2020-08-31 | 2023-04-04 | Bristol Myers Squibb Co | Assinatura de localização celular e imunoterapia |
WO2022087402A1 (fr) | 2020-10-23 | 2022-04-28 | Bristol-Myers Squibb Company | Thérapie par antagoniste de lag-3 pour le cancer du poumon |
WO2022120179A1 (fr) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales et leurs utilisations |
WO2022135667A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Arn thérapeutique pour le traitement du cancer |
WO2022135666A1 (fr) | 2020-12-21 | 2022-06-30 | BioNTech SE | Programme de traitement faisant intervenir des protéines cytokines |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
EP4267172A1 (fr) | 2020-12-28 | 2023-11-01 | Bristol-Myers Squibb Company | Administration sous-cutanée d'anticorps pd1/pd-l1 |
AU2021411486A1 (en) | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
CN112852870B (zh) * | 2021-01-13 | 2022-03-04 | 北京鼎成肽源生物技术有限公司 | IL-18基因融合H2Kk基因在制备增强细胞免疫的细胞中的应用、细胞及制备方法 |
WO2022166987A1 (fr) * | 2021-02-08 | 2022-08-11 | 迈威(上海)生物科技股份有限公司 | Anticorps se liant à lag-3 et leur utilisation |
KR20240005700A (ko) | 2021-03-29 | 2024-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법 |
WO2022240741A1 (fr) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Agents inhibiteurs de lag3 et gal3, peptides xbp1, cs1 et cd138, et leurs méthodes d'utilisation |
CA3225254A1 (fr) | 2021-07-13 | 2023-01-19 | BioNTech SE | Agents de liaison multispecifiques contre cd40 et cd137 en polytherapie du cancer |
CN113603779B (zh) * | 2021-08-18 | 2023-06-02 | 深圳市元谷生物科技有限公司 | 一种结合人淋巴细胞活化基因3(lag-3)的抗体及其用途 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
AU2022375806A1 (en) | 2021-10-29 | 2023-12-14 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
WO2023147371A1 (fr) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Polythérapie pour carcinome hépatocellulaire |
WO2023164638A1 (fr) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Polythérapie pour carcinome colorectal |
WO2023168404A1 (fr) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Méthodes de traitement d'une tumeur |
WO2023170606A1 (fr) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t |
WO2023178329A1 (fr) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Procédés d'isolement de polypeptides |
CN114874324B (zh) * | 2022-05-13 | 2023-02-03 | 苏州旭光科星抗体生物科技有限公司 | 一种检测可溶性lag-3蛋白含量的酶联免疫检测试剂盒及应用 |
WO2023235847A1 (fr) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
CA2096222C (fr) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Genes de fusion selectables et bifonctionnelles |
EP0804590A1 (fr) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd) |
US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
EP0758383B1 (fr) | 1994-05-06 | 2007-01-24 | Institut Gustave Roussy | Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype |
FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
SI1897548T1 (sl) | 2003-02-28 | 2013-12-31 | The Johns Hopkins University | Regulacija celic T |
US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
EP1987839A1 (fr) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes |
EP2044949A1 (fr) * | 2007-10-05 | 2009-04-08 | Immutep | Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
HUE13746964T2 (hu) | 2012-02-06 | 2020-01-28 | Inhibrx Inc | CD47 antitestek és alkalmazási eljárásaik |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
US9574013B2 (en) | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
CN110448566A (zh) | 2013-03-01 | 2019-11-15 | 阿斯泰克斯制药公司 | 药物组合 |
AU2014230741B2 (en) * | 2013-03-15 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
WO2015143343A2 (fr) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique |
US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
WO2015179799A1 (fr) | 2014-05-22 | 2015-11-26 | The General Hospital Corporation | Récepteur dd1alpha et ses utilisations dans des troubles immunitaires |
US20160176962A1 (en) | 2014-10-31 | 2016-06-23 | Oncomed Pharmaceuticals, Inc. | Combination Therapy For Treatment Of Disease |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
WO2021155028A1 (fr) * | 2020-01-29 | 2021-08-05 | Kenjockety Biotechnology, Inc. | Anticorps anti-mdr1 et leurs utilisations |
-
2016
- 2016-02-02 MA MA041463A patent/MA41463A/fr unknown
- 2016-02-03 SG SG10201907161YA patent/SG10201907161YA/en unknown
- 2016-02-03 KR KR1020177024728A patent/KR20170116067A/ko not_active Application Discontinuation
- 2016-02-03 JP JP2017540834A patent/JP6949713B2/ja active Active
- 2016-02-03 CN CN202210381152.5A patent/CN114634573A/zh active Pending
- 2016-02-03 CA CA2975753A patent/CA2975753A1/fr active Pending
- 2016-02-03 BR BR112017016638-0A patent/BR112017016638B1/pt active IP Right Grant
- 2016-02-03 CN CN201680020117.3A patent/CN107428836A/zh active Pending
- 2016-02-03 EP EP16747220.8A patent/EP3253798A4/fr not_active Ceased
- 2016-02-03 EA EA201791742A patent/EA201791742A1/ru unknown
- 2016-02-03 WO PCT/US2016/016424 patent/WO2016126858A2/fr active Application Filing
- 2016-02-03 EP EP21198994.2A patent/EP4011914A1/fr active Pending
- 2016-02-03 US US15/548,405 patent/US10836824B2/en active Active
- 2016-02-03 MX MX2017009904A patent/MX2017009904A/es unknown
- 2016-02-03 SG SG11201706199RA patent/SG11201706199RA/en unknown
-
2017
- 2017-07-30 IL IL253718A patent/IL253718B/en unknown
- 2017-07-31 MX MX2022000112A patent/MX2022000112A/es unknown
- 2017-08-04 ZA ZA2017/05303A patent/ZA201705303B/en unknown
-
2018
- 2018-05-17 HK HK18106454.6A patent/HK1246814A1/zh unknown
- 2018-05-25 HK HK18106890.8A patent/HK1247618A1/zh unknown
-
2019
- 2019-05-01 US US16/400,198 patent/US20190256596A1/en not_active Abandoned
-
2020
- 2020-10-19 US US17/074,269 patent/US20210095026A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114634573A (zh) | 2022-06-17 |
BR112017016638B1 (pt) | 2023-11-07 |
HK1247618A1 (zh) | 2018-09-28 |
IL253718B (en) | 2021-08-31 |
IL253718A0 (en) | 2017-09-28 |
WO2016126858A2 (fr) | 2016-08-11 |
EP3253798A4 (fr) | 2018-07-25 |
HK1246814A1 (zh) | 2018-09-14 |
WO2016126858A3 (fr) | 2016-09-29 |
US20190256596A1 (en) | 2019-08-22 |
JP2018505674A (ja) | 2018-03-01 |
EA201791742A1 (ru) | 2018-01-31 |
US20210095026A1 (en) | 2021-04-01 |
SG11201706199RA (en) | 2017-08-30 |
MX2022000112A (es) | 2022-02-10 |
MX2017009904A (es) | 2018-06-27 |
CA2975753A1 (fr) | 2016-08-11 |
MA41463A (fr) | 2017-12-12 |
US20180127496A1 (en) | 2018-05-10 |
EP3253798A2 (fr) | 2017-12-13 |
CN107428836A (zh) | 2017-12-01 |
ZA201705303B (en) | 2022-12-21 |
KR20170116067A (ko) | 2017-10-18 |
BR112017016638A2 (pt) | 2018-06-19 |
US10836824B2 (en) | 2020-11-17 |
JP6949713B2 (ja) | 2021-10-13 |
EP4011914A1 (fr) | 2022-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022000112A (es) | Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3). | |
MX2023001791A (es) | Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r). | |
MX2019012793A (es) | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. | |
MX2017012429A (es) | Anticuerpos dirigidos contra la inmunoglobulina de celulas t y la proteina mucina 3 (tim-3). | |
MX2015015037A (es) | Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1). | |
MX2020001272A (es) | Anticuerpos dirigidos contra interleucina-33 (il-33). | |
MX2019005116A (es) | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
EA201990747A1 (ru) | Способы лечения иммунных нарушений с применением белков, связывающих pd–1 | |
MX2019005117A (es) | Anticuerpos dirigidos contra la muerte programada 1 (pd-1). | |
WO2018017864A3 (fr) | Agents de liaison à pvrig et leurs utilisations | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
MX2018014979A (es) | Anticuerpos específicos dirigidos contra hla-g. | |
MX2021003685A (es) | Inhibicion dirigida del factor de crecimiento transformador b (tgfb). | |
MD4716C1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
MX2019003058A (es) | Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1). | |
MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
PH12019502298A1 (en) | Monoclonal antibody to pd-l1 | |
MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
CR20220228A (es) | Anticuerpos trem2 y usos de estos | |
MX2020010092A (es) | Variantes de anticuerpo c-terminales. | |
EP4218817A3 (fr) | Méthodes de traitement de maladies métaboliques par inhibition de l'activation de la myostatine | |
MX2020013923A (es) | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. | |
WO2015116569A3 (fr) | Anticorps dirigés contre la famille des récepteurs à domaine discoïdine, élément 1 (ddr1) | |
EA202092981A1 (ru) | Антитела к l1cam и их применение |